BRISTOL-MYERS SQUIBB COMPANY Income Taxes Paid
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Income Taxes Paid of $239.00 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-04-30.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:IncomeTaxesPaidNet · last filed 2026-04-30
- BRISTOL-MYERS SQUIBB COMPANY income taxes paid, net for the quarter ending 2026-03-31 was $239.00M, a 1.70% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY income taxes paid, net for the quarter ending 2025-12-31 was $1.06B, a 33.00% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY income taxes paid, net for the quarter ending 2025-09-30 was $400.00M, a 60.00% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY income taxes paid, net for the quarter ending 2025-06-30 was $1.56B, a 18.19% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY income taxes paid, net for fiscal 2025 was $3.26B, a 16.31% decline from fiscal 2024.
- BRISTOL-MYERS SQUIBB COMPANY income taxes paid, net for fiscal 2024 was $3.90B, a 9.30% decline from fiscal 2023.
- BRISTOL-MYERS SQUIBB COMPANY income taxes paid, net for fiscal 2023 was $4.30B, a 20.37% decline from fiscal 2022.
- BRISTOL-MYERS SQUIBB COMPANY income taxes paid, net for fiscal 2022 was $5.40B, a 54.29% increase from fiscal 2021.
| Period end | Income Taxes Paid, Net 3 month | Income Taxes Paid, Net 6 month | Income Taxes Paid, Net 9 month | Income Taxes Paid, Net 12 month | Income Taxes Paid, Net 12 month as first filed |
|---|---|---|---|---|---|
| 2026-03-31 | $239.00M 10-Q · filed 2026-04-30 | $1.30B derived: sum of 2 quarters · filed 2026-04-30 | $1.70B derived: sum of 3 quarters · filed 2026-04-30 | $3.27B derived: sum of 4 quarters · filed 2026-04-30 | |
| 2025-12-31 | $1.06B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $1.46B derived: sum of 2 quarters · filed 2026-02-11 | $3.03B derived: sum of 3 quarters · filed 2026-02-11 | $3.26B 10-K · filed 2026-02-11 | |
| 2025-09-30 | $400.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $1.97B derived: sum of 2 quarters · filed 2025-10-30 | $2.20B 10-Q · filed 2025-10-30 | $3.00B derived: sum of 4 quarters · filed 2026-04-30 | |
| 2025-06-30 | $1.56B derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $1.80B 10-Q · filed 2025-07-31 | $2.60B derived: sum of 3 quarters · filed 2026-04-30 | $3.60B derived: sum of 4 quarters · filed 2026-04-30 | |
| 2025-03-31 | $235.00M 10-Q · filed 2026-04-30 | $1.03B derived: sum of 2 quarters · filed 2026-04-30 | $2.04B derived: sum of 3 quarters · filed 2026-04-30 | $3.95B derived: sum of 4 quarters · filed 2026-04-30 | |
| 2024-12-31 | $800.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $1.80B derived: sum of 2 quarters · filed 2026-02-11 | $3.71B derived: sum of 3 quarters · filed 2026-02-11 | $3.90B 10-K · filed 2026-02-11 | |
| 2024-09-30 | $1.00B derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $2.91B derived: sum of 2 quarters · filed 2025-10-30 | $3.10B 10-Q · filed 2025-10-30 | $3.30B derived: sum of 4 quarters · filed 2026-02-11 | |
| 2024-06-30 | $1.91B derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $2.10B 10-Q · filed 2025-07-31 | $2.30B derived: sum of 3 quarters · filed 2026-02-11 | $3.30B derived: sum of 4 quarters · filed 2026-02-11 | |
| 2024-03-31 | $187.00M 10-Q · filed 2025-04-24 | $387.00M derived: sum of 2 quarters · filed 2026-02-11 | $1.39B derived: sum of 3 quarters · filed 2026-02-11 | $4.34B derived: sum of 4 quarters · filed 2026-02-11 | |
| 2023-12-31 | $200.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $1.20B derived: sum of 2 quarters · filed 2026-02-11 | $4.15B derived: sum of 3 quarters · filed 2026-02-11 | $4.30B 10-K · filed 2026-02-11 | |
| 2023-09-30 | $1.00B derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $3.95B derived: sum of 2 quarters · filed 2024-10-31 | $4.10B 10-Q · filed 2024-10-31 | $5.60B derived: sum of 4 quarters · filed 2025-02-12 | |
| 2023-06-30 | $2.95B derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-26 | $3.10B 10-Q · filed 2024-07-26 | $4.60B derived: sum of 3 quarters · filed 2025-02-12 | $5.80B derived: sum of 4 quarters · filed 2025-02-12 | |
| 2023-03-31 | $149.00M 10-Q · filed 2024-04-25 | $1.65B derived: sum of 2 quarters · filed 2025-02-12 | $2.85B derived: sum of 3 quarters · filed 2025-02-12 | $5.29B derived: sum of 4 quarters · filed 2025-02-12 | |
| 2022-12-31 | $1.50B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $2.70B derived: sum of 2 quarters · filed 2025-02-12 | $5.14B derived: sum of 3 quarters · filed 2025-02-12 | $5.40B 10-K · filed 2025-02-12 | |
| 2022-09-30 | $1.20B derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-26 | $3.65B derived: sum of 2 quarters · filed 2023-10-26 | $3.90B 10-Q · filed 2023-10-26 | ||
| 2022-06-30 | $2.44B derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-27 | $2.70B 10-Q · filed 2023-07-27 | |||
| 2022-03-31 | $255.00M 10-Q · filed 2023-04-27 | ||||
| 2021-12-31 | $3.50B 10-K · filed 2024-02-13 | ||||
| 2020-12-31 | $3.40B 10-K · filed 2023-02-14 | ||||
| 2019-12-31 | $1.50B 10-K · filed 2022-02-09 | $1.50B 10-K · filed 2020-02-24 | |||
| 2018-12-31 | $747.00M 10-K · filed 2021-02-10 | ||||
| 2017-12-31 | $546.00M 10-K · filed 2020-02-24 | ||||
| 2016-12-31 | $2.00B 10-K · filed 2019-02-25 | $2.04B 10-K · filed 2017-02-21 | |||
| 2015-12-31 | $577.00M 10-K · filed 2018-02-13 | ||||
| 2014-12-31 | $544.00M 10-K · filed 2017-02-21 | ||||
| 2013-12-31 | $478.00M 10-K · filed 2016-02-12 | ||||
| 2012-12-31 | $676.00M 10-K · filed 2015-02-13 | ||||
| 2011-12-31 | $597.00M 10-K · filed 2014-02-14 | ||||
| 2010-12-31 | $672.00M 10-K · filed 2013-02-15 | ||||
| 2009-12-31 | $885.00M 10-K · filed 2012-02-17 | ||||
| 2008-12-31 | $636.00M 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |